Praxis Precision Medicines Inc. (NASDAQ: PRAX) announced results from its Phase 2 RADIANT study of vormatrigine in patients with focal onset seizures. The 8-week study showed a 56.3% median reduction in seizure frequency, according to the company's statement.

Approximately 22% of patients achieved complete seizure elimination during the final 28 days of treatment. More than 54% of patients reached a 50% reduction in seizures within the first week of treatment, the company reported.

Vormatrigine was described as generally well tolerated with what the company characterized as a favorable safety profile. The drug candidate is being developed as a once-daily oral treatment for adult focal onset seizures and generalized epilepsy.

"We are thrilled by the best-in-disease topline results of this first cohort for the RADIANT study and for the potential to deliver a fast-acting, highly efficacious and tolerable therapy to patients living with focal epilepsy," said Marcio Souza, president and chief executive officer of Praxis.

Dr. Jacqueline French, Professor at NYU Langone Health's Comprehensive Epilepsy Center, commented that while several sodium channel therapies already treat focal onset seizures, "there remains substantial room for improvement within this class."

The company plans to complete its pivotal 12-week POWER1 study in the fourth quarter and expects to initiate the POWER2 study based on the RADIANT results. Additional data will be presented at the 36th International Epilepsy Congress on August 31, 2025, in Lisbon, Portugal.

Praxis is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance.